ROME — Fewer drops are in the future of glaucoma treatment, according to one specialist speaking at the OSN Italy meeting. More laser and new injectable sustained-release devices will alleviate the burden of multiple daily medications, improving compliance and consistency of results.
“In the LiGHT trial, 74% of first-line SLT-treated patients remained drop-free at 36 months, and the target IOP was maintained in 93% of visits. One of the biggest things was that surgery was entirely avoided for these patients, whereas with medications 11 patients underwent a surgical procedure. This
Uncategorized